Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AbTCR (anti-CD19/CD22)-T Cells in R/R B-cell Lymphoma
NCT07168291Phase 1Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell lymphoma, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Incidence of Treatment-related Adverse Events at 3 years. Planned start Dec 2025; status: not yet recruiting.
02
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07168291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168291.